Cellectar Biosciences
Open
$2.65
Prev. Close
$2.65
High
$2.65
Low
$2.63
Market Snapshot
$10.85M
-0.5
-39.55
11
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
emptyResult
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Recently from Cashu
Cellectar Biosciences Set for Key Earnings Report Amid Cancer Therapeutics Advancements
Cellectar Biosciences: Focusing on Advancements in Cancer Therapeutics Cellectar Biosciences stands at a critical juncture as it prepares to release its quarterly earnings report on March 4, 2026. As…
Cellectar Biosciences: Innovating Targeted Cancer Therapies with CLR 131
Cellectar Biosciences: Advancements in Cancer Therapeutics Cellectar Biosciences focuses on developing innovative treatment options for cancer, leveraging its proprietary phospholipid ether drug deliv…
Cellectar Biosciences Readies for Key Earnings Report Amid Oncology Innovations
Cellectar Biosciences Prepares for Critical Earnings Report Amid Oncology Innovations Cellectar Biosciences is on the brink of releasing its quarterly earnings report on November 13, 2025, a significa…
Cellectar Biosciences Advances Cancer Treatment with Innovative Radiopharmaceutical CLR 131
Cellectar Biosciences Advances Radiopharmaceutical Therapy for Cancer Treatment Cellectar Biosciences, a leader in developing targeted therapies for cancer treatment, is making significant strides wit…